Key Stats for Eli Lilly Stock
- Past week’s performance: +13.7%
- 52-week range: $624 to $1,134
- Valuation model target price: $466
- Implied upside: +51.5% over 2.7 years
Value your favorite stocks like LLY with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Eli Lilly and Company (LLY) delivered one of the most impressive earnings beats in the large-cap pharmaceutical sector this quarter. Adjusted earnings per share came in at $8.55, far above the analyst estimate of $6.66. And the stock responded strongly, gaining 13.7% over the past week.
Surging demand for Lilly’s weight-loss and diabetes drugs drove the outperformance. Lilly raised its full-year profit forecast, and management struck a confident tone. Wall Street analysts quickly noted that concerns over a liver failure signal tied to its weight-loss drug were an overreaction, per Reuters.
The FDA’s proposal to curb mass compounding of Lilly’s weight-loss drugs is a meaningful tailwind. Compounders are pharmacies that produce their own versions of branded drugs like Zepbound. Limiting their activity protects Lilly’s branded sales and should improve revenue quality over time.
Going forward, the two most critical drivers investors are watching are Lilly’s new oral GLP-1 pill called Foundayo and the emerging Phase 3 data for its next-generation weight-loss drug, retatrutide.
See analysts’ growth forecasts and price targets for LLY (It’s free) >>>
Is Eli Lilly Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 18.9%
- Operating Margins: 45%
- Exit P/E Multiple: 26.4x
Based on these inputs, the model estimates a target price of $1,466, implying a 51.5% total return from the current share price and a 16.9% annualized return over the next 2.7 years.
The 18.9% revenue CAGR is the central assumption, and it is well supported by recent performance. Lilly grew revenue 44.7% in the past year alone, so the model is actually projecting meaningful deceleration. But with the obesity market still early in its global adoption curve, 18.9% growth looks conservative rather than ambitious.
The 45% operating margin assumption reflects a slight contraction from current levels. Lilly’s EBIT margin has already run at 47.3% over the past 12 months. So the model is building in margin investment as Lilly expands manufacturing, funds new trials, and pursues acquisitions.
At around $968, Lilly trades at roughly 26x forward earnings. But that multiple looks fair given the earnings growth rate and the durability of the obesity drug franchise. The five-year EPS growth rate of 45% per year confirms Lilly is compounding at a pace that few companies at this scale can match.
What’s Driving LLY Stock Going Forward?
Foundayo, Lilly’s oral GLP-1 pill for weight loss and obesity, is the most important near-term commercial catalyst. The pill reached nearly 6,000 prescriptions in its third week on the market. An oral format removes the biggest adoption barrier for patients who are hesitant about injectable drugs like Zepbound or Mounjaro.
Retatrutide is the next pipeline drug that could redefine what weight-loss medications can achieve. Phase 3 clinical data showed average weight loss of up to 71.2 pounds among study participants. If approved, this could position retatrutide as the most powerful anti-obesity drug ever brought to the market.
Lilly is also investing aggressively in manufacturing to meet surging global demand. The company committed over $6 billion to a new facility in Huntsville, Alabama. It is also investing 20 billion yen in Japan production capacity to address growing demand in international markets.
Acquisitions are adding further pipeline depth and long-term optionality. Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, and a $2 billion AI drug development deal with Insilico Medicine signals that Lilly is investing in discovery acceleration beyond its current obesity drug franchise.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Eli Lilly?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up LLY, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track LLY alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Eli Lilly stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
